Wake Forest first to apply innovative brain cancer treatment

July 23, 1999

WINSTON-SALEM, N.C. -- Wake Forest University Baptist Medical Center recently became the first medical center to use an innovative treatment system for brain cancer known as the GliaSite Radiation Therapy System (RTS).

The Medical Center is one of five National Cancer Institute (NCI)-affiliated facilities conducting clinical trials of the investigational device. Developed by Proxima Therapeutics, the GliaSite RTS places a high dose of radiation directly into the tissue most likely to contain residual cancer cells following tumor removal.

The device is implanted during the same surgical procedure conducted to remove the tumor and is later filled with a liquid radiation source. Both are removed within several weeks, completing the treatment.

According to Stephen B. Tatter, M.D., Ph.D., attending neurosurgeon at the Medical Center, radiation is the most effective treatment for many malignant brain tumors. However, current technology prevents doctors from delivering high enough doses to stop many tumors from recurring. Tatter is principal investigator of the clinical trials at the Medical Center and national chairman for the study.

"Implanting radiation directly into the tumor, or brachytherapy, is the most promising technique to accomplish this," said Tatter. "Unfortunately, previous attempts at brachytherapy were extremely inconvenient for patients, and had a high rate of complications such as infection and the need for another operation. The Proxima GliaSite RTS is an investigational device designed to address these issues, making brachytherapy more convenient and safe."

The American Cancer Society projects 18,000 Americans will be diagnosed this year with malignant brain tumors. Nearly all experience tumor regrowth after initial treatment.

Studies indicate survival for patients with recurrent malignant brain tumors is approximately three months without therapeutic measures, five months with surgery alone, eight months with surgery and chemotherapy and 15 months with surgery and internal radiation.

Clinical trials evaluating the patented cancer treatment system are being conducted under the guidance of the NCI's New Approaches to Brain Tumor Therapy program. Other medical centers testing the device are: Johns Hopkins University School of Medicine, Baltimore; Emory University School of Medicine, Atlanta; Henry Ford Hospital, Detroit; and, University of Texas Health Science Center at San Antonio.
-end-
Contact: Jim Steele, 336-716-4587, Wake Forest University Baptist Medical Center; or for Proxima Therapeutics, Inc., Debbie Wetherhead, 770-971-9692.



Wake Forest Baptist Medical Center

Related Brain Cancer Articles from Brightsurf:

Glioblastoma nanomedicine crosses into brain in mice, eradicates recurring brain cancer
A new synthetic protein nanoparticle capable of slipping past the nearly impermeable blood-brain barrier in mice could deliver cancer-killing drugs directly to malignant brain tumors, new research from the University of Michigan shows.

Cancer cells mediate immune suppression in the brain
Notre Dame researchers showed that one type of cell important for immunity, called a myeloid cell, can suppress the immune response -- which has the effect of allowing breast cancer cells to metastasize to the brain to form secondary tumor cells there.

New therapy targets breast cancer metastases in brain
When breast cancer spreads to the brain, the prognosis is grim.

AI may help brain cancer patients avoid biopsy
Brain cancer patients in the coming years may not need to go under the knife to help doctors determine the best treatment for their tumors.

Lung cancer therapy may improve outcomes of metastatic brain cancer
A medication commonly used to treat non-small cell lung cancer that has spread, or metastasized, may have benefits for patients with metastatic brain cancers, suggests a new review and analysis led by researchers at St.

Finding new clues to brain cancer treatment
Researchers at Case Western Reserve University School of Medicine and Cleveland Clinic new discovered a more accurate way to determine the relative life expectancy of glioblastoma victims and identify who could be candidates for experimental clinical drug trials by blending information from Artificial Intelligence (AI)--in this case, computer image analysis of the initial MRI scans taken of brain cancer patients--and genomic research.

Dynamic transition of the blood-brain barrier in the development of non-small cell lung cancer brain
Effective drug delivery through the BTB is one of the greatest therapeutic obstacles in treating brain metastases.

Blood test could help to accelerate brain cancer diagnosis
A blood test which could help to accelerate the diagnosis of brain cancer has been developed in research led at the University of Strathclyde.

The 'Goldilocks' principle for curing brain cancer
University of Minnesota Medical School researchers found that a stable body temperature holds the key to awakening the body's immune response to fight off brain cancer.

The path of breast-to-brain cancer metastasis
Scientists at EPFL's Swiss Institute for Experimental Cancer Research have discovered a signaling pathway that breast tumors exploit to metastasize to the brain.

Read More: Brain Cancer News and Brain Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.